Antibodies

abagovomab

abagovomab

Abelacimab (anti-Factor XI) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin.

Abelacimab (anti-Factor XI) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin.

Abelacimab (anti-Factor XI) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin.

Abelacimab (anti-Factor XI) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin.

Abituzumab (anti-ITGAV) is a recombinant monoclonal antibody to ITGAV. Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.Purity&gt95%

Abituzumab (anti-ITGAV) is a recombinant monoclonal antibody to ITGAV. Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.Purity&gt95%

Abituzumab (anti-ITGAV) is a recombinant monoclonal antibody to ITGAV. Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.Purity&gt95%

Abituzumab (anti-ITGAV) is a recombinant monoclonal antibody to ITGAV. Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.Purity&gt95%

abrezekimab

abrezekimab